Serological and molecular testing in viral hepatitis: An update

Canadian Journal of Gastroenterology

Volumn 15, Issue 3, 2001, Pages 177-184

  Weston, S R ^a   Martin, P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis; Viral hepatitis

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M ANTIBODY;

ACUTE HEPATITIS; CHRONIC HEPATITIS; CONTROLLED STUDY; DELTA AGENT HEPATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; TREATMENT PLANNING; VIRUS HEPATITIS; VIRUS LOAD;

EID: 0034807573     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/390294     Document Type: Review

References (63)

1. Serological diagnosis of viral hepatitis
2. Diagnostic approach
3. Diagnostic tools in the evaluations of patients with viral hepatitis undergoing liver transplantation
4. Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test
5. Comparison of four methods for quantitative measurement of hepatitis B viral DNA
6. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays
7. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
8. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: Performance of three commercial assays
9. A multicenter study evaluation of the digene hybrid capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards
10. Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study
11. The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection
12. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay
13. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: Implications for interferon therapy
14. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance
15. Diagnostic tests for hepatitis C
16. Diagnosis of hepatitis C
17. Serological tests for HCV infection
18. Quantitative antibody responses to structural (core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: Impact of epitope variation and relationship to blood
19. Failure of third-generation recombinant immunoblot assay to detect hepatitis C virus core antibodies
20. Hepatitis C virus infections in dialysis centers in the Netherlands: A national survey by serological and molecular methods
21. Diagnosis of hepatitis C virus infection by ELISA, RIBA, and RT-PCR: A comparative evaluation
22. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
23. Automated RIBA hepatitis C virus (HCV) strip immunoblot assay for reproducible HCV diagnosis
24. A French consensus conference on hepatitis C: Screening and treatment
25. Is an "a la carte" combination interferon-alfa-2b plus rebavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
26. Immunogenicity of variable regions of hepatitis C virus proteins: Selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA
27. Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients
28. Quantification of serum hepatitis C virus RNA
29. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha
30. Comparison of 3 quantitative HCV RNA assays - Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C
31. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon
32. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
33. Second generation of the automated cobas amplicor HCV assay improves sensitivity of hepatitis C virus RNA
34. Should we test hepatitis C virus genotype and viremia level in patients with chronic hepatitis C?
35. Quantitative measurement of serum HCV RNA in patient with chronic hepatitis C: Comparison between amplicor HCV Monitor system and branched DNA signal amplification assay
36. Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on type HCV genotype
37. Performance of an automated system for quantification of hepatitis C virus RNA
38. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination
39. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C
40. Quantitative measurement of HCV RNA in the serum: A comparison of three assays based on different principles
41. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon
42. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays
43. Low virological response to interferon in children with chronic hepatitis C
44. Hepatitis C virus quantitation: Optimization of strategies for detecting low-level viremia
45. Measuring hepatitis C viremia in clinical samples: Can we trust the assays?
46. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
47. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection
48. Quantitative measurement of HCV RNA in the serum: A comparison of three assays based on different principles
49. Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment of patients with chronic hepatitis C virus
50. Factors predictive of a beneficial response to therapy of hepatitis C
51. Future directions in the treatment of patients with chronic hepatitis C viral infection
52. New treatment for hepatitis C
53. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
54. Early predictors of response to treatment in patients with chronic hepatitis C
55. Real-time detection system for quantification of hepatitis C virus genome
56. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA
57. Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay
58. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection
59. Hepatocellular carcinoma in patients infected with different hepatitis C genotypes
60. Relationship between hepatocellular carcinoma and subtypes of hepatitis C virus: A nationwide analysis
61. Severity of liver disease in liver transplant recipients with hepatitis C virus infection: Relationship to genotypes and level of viremia
62. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
63. Evaluation of assays for antibody to hepatitis E virus by a serum panel